Entheon Biomedical has received conditional approval from the CSE to commence public trading.
Entheon Biomedical has received conditional approval from the CSE to commence public trading.
MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
The latest psychedelic drug company to commence public trading is Psyched Wellness.
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
Mydecine begins the dual listing process to obtain an LSE listing.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now